Skip to main content

If You Change the Way You Look at Things, Things You Look at Change. Max Planck’s Challenge for Health, Health Care, and the Healthcare System

  • Chapter
  • First Online:
Embracing Complexity in Health

Abstract

Max Planck observed that ‘If you change the way you look at things, things you look at change’. It is high time for healthcare professionals to embrace the challenge—the linear reductionist view of health and disease is failing our patients, our profession and our societies. These insights are not really new, Osler has coined many aphorisms to emphasise the need to understand the person with an illness over and above the diseases that might be responsible for his predicament.

This chapter looks at health, health care and the healthcare system from a complex adaptive systems perspective—health is a subjective adaptive state, health care ought to aim at improving or at least maintaining the experience of health, and the health system ought to provide an integrated framework so that health for all can emerge. Looking at health, health care and the health system from the multiple dimensions spanning basic physiology and its networks to the organisational levels with the power to create an environment in which individuals can achieve their health potentials indeed makes ‘things we look at change’.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Chronic stress results in brain remodelling:

    • Atrophy of the prefrontal cortex—impaired decision making, loss of working memory and loss of fear memory—impulse disorders, increased vigilance

    • Atrophy of the hippocampus—impaired contextual, temporal and spatial memory, and mood dysregulation

    • Initial hypertrophy, later atrophy of the amygdala—increased fear and anxiety, PTSD-like symptoms and impaired aggression control

  2. 2.

    It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has.—William Osler.

  3. 3.

    A surrogate is a laboratory measure or a physical sign that is intended to be used as a substitute for a clinically meaningful endpoint, e.g. reduction in tumour size as a measure of effectiveness of chemotherapy; low cholesterol as a measure of low cardiovascular risk; and rating scales as measures of disease/pain/distress/mood.

  4. 4.

    Often referred to as Zeitgeist.

  5. 5.

    Remember—the p-value is a function of sample size, the larger the sample size required to achieve a ‘p-value ≤ 0.05, the more likely it is that the difference is pragmatically meaningless [102].

  6. 6.

    Countable does not equate to accountable.

References

  1. White K, Williams F, Greenberg B. The ecology of medical care. N Engl J Med. 1961;265(18):885–92.

    Article  CAS  PubMed  Google Scholar 

  2. Green L, Fryer G, Yawn B, Lanier D, Dovey S. The ecology of medical care revisited. N Engl J Med. 2001;344(26):2021–5.

    Article  CAS  PubMed  Google Scholar 

  3. Johansen ME, Kircher SM, Huerta TR. Reexamining the ecology of medical care. N Engl J Med. 2016;374(5):495–6.

    Article  PubMed  Google Scholar 

  4. Braun RN. Die gezielte Diagnostik in der Praxis. Stuttgart: Schattauer; 1957.

    Google Scholar 

  5. Fink W, Kipatov V, Konitzer M. Diagnoses by general practitioners: accuracy and reliability. Int J Forecasting. 2009;25(4):784–93.

    Article  Google Scholar 

  6. Britt H, Miller G, Henderson J, Charles J, Valenti L, Harrison C, Bayram C, Zhang C, Pollack A, O’Halloran J, Pan Y. General practice activity in Australia 2011–12. Sydney: 2012 Contract No.: General Practice Series No. 31.

    Google Scholar 

  7. Sturmberg JP. Health: a personal complex-adaptive state. In: Sturmberg JP, Martin CM, editors. Handbook of systems and complexity in health. New York: Springer; 2013. p. 231–42.

    Chapter  Google Scholar 

  8. Sturmberg JP. The personal nature of health. J Eval Clin Pract. 2009;15(4):766–9.

    Article  PubMed  Google Scholar 

  9. Sturmberg JP. Person-centeredness - a paradigm shift for health care? From disease as a “structural problem” to health, illness and disease as the “emergent outcomes of complex adaptive physiological network function”. In: Loughlin M, editor. Person Centred Care: the new Professionalism. Understanding the Philosopy. 2019: (Forthcoming)

    Google Scholar 

  10. Mackenbach JP. Carl von Linne, Thomas McKeown, and the inadequacy of disease classifications. Eur J Pub Health. 2004;14(3):225.

    Article  Google Scholar 

  11. Macklem PT, Seely A. Towards a definition of life. Perspect Biol Med. 2010;53(3):330–40.

    Article  PubMed  Google Scholar 

  12. Que C-L, Kenyon CM, Olivenstein R, Macklem PT, Maksym GN. Homeokinesis and short-term variability of human airway caliber. J Appl Physiol. 2001;91(3):1131–41.

    Article  CAS  PubMed  Google Scholar 

  13. Sturmberg JP, Bennett JM, Picard M, Seely AJE. The trajectory of life. Decreasing physiological network complexity through changing fractal patterns. Front Physiol. 2015;6:169.

    PubMed  Google Scholar 

  14. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. The human disease network. Proc Natl Acad Sci. 2007;104(21):8685–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Heng HH. Heterogeneity-mediated cellular adaptation and its trade-off: searching for the general principles of diseases. J Eval Clin Pract. 2017;23(1):233–7.

    Article  PubMed  Google Scholar 

  16. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117(2):289–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat. Rev. Immunol. 2005;5:243–51.

    Article  CAS  PubMed  Google Scholar 

  18. Cole SW. Social regulation of human gene expression: mechanisms and implications for public health. Am J Public Health. 2013;103(S1):S84–S92.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wallace DC. A mitochondrial bioenergetic etiology of disease. J Clin Invest. 2013;123(4):1405–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Picard M, Juster R-P, McEwen BS. Mitochondrial allostatic load puts the ‘gluc’ back in glucocorticoids. Nat Rev Endocrinol. 2014;10(5):303–10.

    Article  CAS  PubMed  Google Scholar 

  21. Kaur H, Carvalho J, Looso M, Singh P, Chennupati R, Preussner J, Günther S, Albarrán-Jurez J, Tischner D, Classen S, Offermanns S, Wettschureck N. Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system. Nat. Commun. 2017;8:15700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Luo C, Keown CL, Kurihara L, Zhou J, He Y, Li J, Castanon R, Lucero J, Nery JR, Sandoval JP, Bui B, Sejnowski TJ, Harkins TT, Mukamel EA, Behrens MM, Ecker JR. Single-cell methylomes identify neuronal subtypes and regulatory elements in mammalian cortex. Science. 2017;357(6351):600–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Heng HH. Debating cancer: the paradox in cancer research. Singapore: World Scientific Publishing; 2016.

    Google Scholar 

  24. Karatoreos IN, McEwen BS. Annual research review: the neurobiology and physiology of resilience and adaptation across the life course. J Child Psychol Psychiatry. 2013;54(4):337–47.

    Article  PubMed  Google Scholar 

  25. Lazarus RS, Folkman S. Stress, appraisal, and coping. New York: Springer; 1984.

    Google Scholar 

  26. Antonovsky A. Health, stress and coping. San Francisco: Jossey-Bass; 1979.

    Google Scholar 

  27. Antonovsky A. Complexity, conflict, chaos, coherence, coercion and civility. Soc Sci Med. 1993;37(8):969–74.

    Article  CAS  PubMed  Google Scholar 

  28. Rohleder NP. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom Med. 2014;76(3):181–9.

    Article  PubMed  Google Scholar 

  29. Wolf JM, Rohleder N, Bierhaus A, Nawroth PP, Kirschbaum C. Determinants of the NF-κB response to acute psychosocial stress in humans. Brain Behav Immun. 2009;23(6):742–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003;100(4):1920–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rohleder N, Marin TJ, Ma R, Miller GE. Biologic cost of caring for a cancer patient: dysregulation of pro- and anti-inflammatory signaling pathways. J Clin Oncol. 2009;27(18):2909–15.

    Article  PubMed  Google Scholar 

  32. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, Turner RB. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 2012;109(16):5995–9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Picard M, McEwen BS. Psychological stress and mitochondria: a conceptual framework. Psychosom Med. 2018;80(2):126–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Picard M, McEwen BS. Mitochondria impact brain function and cognition. Proc Natl Acad Sci. 2014;111(1):7–8.

    Article  CAS  PubMed  Google Scholar 

  35. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med. 2011;208(3):417–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Barabási A-L. Network medicine - from obesity to the “diseasome”. N Engl J Med. 2007;357(4):404–7.

    Article  PubMed  Google Scholar 

  37. Sturmberg JP, Bennett JM, Martin CM, Picard M. ‘Multimorbidity’ as the manifestation of network disturbances. J Eval Clin Pract. 2017;23(1):199–208.

    Article  PubMed  Google Scholar 

  38. Sturmberg JP, Picard M, Aron DC, Bennett JM, Bircher J, deHaven MJ, Gijzel SMW, Heng HH, Marcum JA, Martin CM, Miles A, Peterson CL, Rohleder N, Walker C, Rikkert MGMO, Melis RJF. Health and disease - how network physiology integrates the social and biological determinants of health. A framework for debate. Front Med. 2019;6:59.

    Google Scholar 

  39. Bennett JM, Reeves G, Billman G, Sturmberg JP. Inflammation, the body’s only efficient way to respond to injuries: implications for clinical care of chronic diseases. Front Med. 2018;(5):316

    Article  Google Scholar 

  40. Sterling P, Eyer J. Allostasis: a new paradigm to explain arousal pathology. In: Fisher S, Reason J, editors. Handbook of life stress, cognition and health. New York: Wiley; 1988. p. 629–49.

    Google Scholar 

  41. McEwen BS. Stress, adaptation, and disease: allostasis and allostatic load. Ann N Y Acad Sci. 1998;840(1):33–44.

    Article  CAS  PubMed  Google Scholar 

  42. McEwen B. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367–81.

    PubMed  PubMed Central  Google Scholar 

  43. McEwen B. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367–81.

    PubMed  PubMed Central  Google Scholar 

  44. Edes AN, Crews DE. Allostatic load and biological anthropology. Am J Phys Anthropol. 2017;162(S63):e23146.

    Article  Google Scholar 

  45. Juster R-P, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev. 2010;35(1):2–16.

    Article  PubMed  Google Scholar 

  46. Read S, Grundy E. Allostatic load - a challenge to measure multisystem physiological dysregulation. National Centre for Research Methods Working Paper 04/12; 2012. http://eprints.ncrm.ac.uk/2879/1/NCRM_workingpaper_0412.pdf.

  47. Loucks EB, Juster RP, Pruessner JC. Neuroendocrine biomarkers, allostatic load, and the challenge of measurement: a commentary on Gersten. Soc Sci Med. 2008;66(3):525–30.

    Article  Google Scholar 

  48. Robertson T, Beveridge G, Bromley C. Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: evidence from the Scottish health survey. PLos One. 2017;12(8):e0183297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wiley JFP, Gruenewald TLP, Karlamangla ASMDP, Seeman TEP. Modeling multisystem physiological dysregulation. Psychosom Med. 2016;78(3):290–301.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Arbeev KG, Ukraintseva SV, Bagley O, Zhbannikov IY, Cohen AA, Kulminski AM, Yashin AI. “Physiological dysregulation” as a promising measure of robustness and resilience in studies of aging and a new indicator of preclinical disease. J Gerontol A Biol Sci Med Sci. 2018. https://doi.org/10.1093/gerona/gly136.

  51. Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci. 2001;98(8): 4770–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Seeman TE, Crimmins E, Huang M-H, Singer B, Bucur A, Gruenewald T, Berkman LF, Reuben DB. Cumulative biological risk and socio-economic differences in mortality: MacArthur studies of successful aging. Soc Sci Med. 2004;58(10):1985–97.

    Article  PubMed  Google Scholar 

  53. Lakoff G, Johnsen M. Metaphors we live by. London: The University of Chicago Press; 2003.

    Book  Google Scholar 

  54. Pellegrino E, Thomasma D. A philosophical basis of medical practice. Towards a philosophy and ethic of the healing professions. Oxford: Oxford University Press; 1981.

    Google Scholar 

  55. McWhinney IR. An acquaintance with particulars …. Fam Med. 1989;21(4):296–8.

    Google Scholar 

  56. McWhinney IR. Being a GP - what it means. WONCA 2000. 2000 05-07-2000. p. 4.

    Google Scholar 

  57. Hart JT. Expectations of health care: promoted, managed or shared? Health Expect. 1998;1(1):3–13.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Stewart MA. Effective physician-patient communication and health outcomes: a review. Can Med Assoc J. 1995;152(9):1423–33.

    CAS  Google Scholar 

  59. Matusitz J, Spear J. Effective doctor-patient communication: an updated examination. Social Work in Public Health. 2014;29(3):252–66.

    Article  PubMed  Google Scholar 

  60. Singh Ospina N, Phillips KA, Rodriguez-Gutierrez R, Castaneda-Guarderas A, Gionfriddo MR, Branda ME, Montori VM. Eliciting the patient’s agenda - secondary analysis of recorded clinical encounters. J Gen Intern Med. 2019;34:36–40.

    Article  PubMed  Google Scholar 

  61. Davis F. The cabdriver and his fare: facets of a fleeting relationship. Am J Sociol. 1959;65(2):158–65.

    Article  Google Scholar 

  62. McKinlay JB, Marceau LD. The end of the golden age of doctoring. Int J Health Serv. 2002;32(2):379–416.

    Article  PubMed  Google Scholar 

  63. Osorio JH. Evolution and changes in the physician-patient relationship. Colomb Méd. 2011;42:400–5.

    Google Scholar 

  64. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, for Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Board on health care services. In: Institute of Medicine, editors. Clinical practice guidelines we can trust. Washington: The National Academics Press; 2011. Available at http://nap.edu/13058.

  65. Samanta A, Mello MM, Foster C, Tingle J, Samanta J. The role of clinical guidelines in medical negligence litigation: a shift from the BOLAM standard? Med Law Rev. 2006;14(3):321–66.

    Article  PubMed  Google Scholar 

  66. Lenzer J. Why we can’t trust clinical guidelines. Br Med J. 2013;346:f3830.

    Article  Google Scholar 

  67. Fleming T, DeMets D. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605–13.

    Article  CAS  PubMed  Google Scholar 

  68. Institute of Medicine. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington: The National Academies Press (Institute of Medicine); 2010.

    Google Scholar 

  69. Moynihan R. Surrogates under scrutiny: fallible correlations, fatal consequences. Br Med J. 2011;343:d5160.

    Article  Google Scholar 

  70. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973–84.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. Eur Heart J. 2015;36(33):2212–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Krumholz HM, Lee TH. Redefining quality - implications of recent clinical trials. N Engl J Med. 2008;358(24):2537–9.

    Article  CAS  PubMed  Google Scholar 

  73. Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15(1):134.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. Br Med J. 2011;343:d7995.

    Article  Google Scholar 

  75. Mercuri M, Sherbino J, Sedran RJ, Frank J, Gafni A, Norman GP. When guidelines don’t guide: the effect of patient context on management decisions based on clinical practice guidelines. Acad Med. 2015;90(2):191–6.

    Article  PubMed  Google Scholar 

  76. Weisz G, Cambrosio A, Keating P, Knaapen L, Schlich T, Tournay VJ. The emergence of clinical practice guidelines. Milbank Q. 2007;85(4):691–727.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Rosenberg CE. Disease in history: frames and framers. Milbank Q. 1989;67(Suppl 1):1–15.

    Article  PubMed  Google Scholar 

  78. Brown P. Naming and framing: the social construction of diagnosis and illness. J Health Soc Behav. 1995;35(Extra Issue):34–52.

    Google Scholar 

  79. Aronowitz RA. When do symptoms become a disease? Ann Intern Med. 2001;134(9(pt 2)):803–308.

    Google Scholar 

  80. Rosenberg CE. The tyranny of diagnosis: specific entities and individual experience. Milbank Q. 2002;80(2):237–60.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. Br Med J. 2002;324:886–91.

    Article  Google Scholar 

  82. Rosenberg CE. What is disease? In memory of Owsei Temkin. Bull Hist Med. 2003;77(3):491–505.

    Article  PubMed  Google Scholar 

  83. Sturmberg JP, Martin CM. Diagnosis - the limiting focus of taxonomy. J Eval Clin Pract. 2016;22(1):103–11.

    Article  PubMed  Google Scholar 

  84. Manrai AK, Patel CJ, Ioannidis JA. In the era of precision medicine and big data, who is normal? JAMA. 2018;319(19):1981–2.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JKV, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PVK, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–13.

    Google Scholar 

  86. Heng HHQ. Cancer genome sequencing: the challenges ahead. Bioessays. 2007;29(8): 783–94.

    Article  PubMed  Google Scholar 

  87. Faber R, Baumert M, Stepan H, Wessel N, Voss A, Walther T. Baroreflex sensitivity, heart rate, and blood pressure variability in hypertensive pregnancy disorders. J Hum Hypertens. 2004;18:707.

    Article  CAS  PubMed  Google Scholar 

  88. Mussalo H, Vanninen E, Ikäheimo R, Laitinen T, Hartikainen J. Short-term blood pressure variability in renovascular hypertension and in severe and mild essential hypertension. Clin Sci. 2003;105(5):609–14.

    Article  Google Scholar 

  89. Kario K. Blood pressure variability in hypertension. A possible cardiovascular risk factor. Am J Hypertens. 2004;17(11):1075–6.

    PubMed  Google Scholar 

  90. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.

    Article  PubMed  Google Scholar 

  91. Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018;39(24):2243–51.

    Article  PubMed  Google Scholar 

  92. Jun JE, Jin S-M, Baek J, Oh S, Hur KY, Lee M-S, Lee M-K, Kim JH. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care. 2015;38(8):1610–4.

    Article  CAS  PubMed  Google Scholar 

  94. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C, on behalf of IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Aussem A, Caille P, Klemm Z, Gasse M, Anne-MarieSchott, Ducher M. Analysis of risk factors of hip fracture with causal Bayesian networks. In: Proceedings IWBBIO. Granada: Copicentro 2014. p. 1074–85.

    Google Scholar 

  96. Russ TC, Gatz M, Pedersen NL, Hannah J, Wyper G, Batty GD, Deary IJ, Starr JM. Geographical variation in dementia: examining the role of environmental factors in Sweden and Scotland. Epidemiology. 2015;26(2):263–70.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Caillet P, Klemm S, Ducher M, Aussem A, Schott A-M. Hip fracture in the elderly: a re-analysis of the EPIDOS study with causal Bayesian networks. PLoS One. 2015;10(3):e0120125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Stopford CL, Snowden JS, Thompson JC, Neary D. Variability in cognitive presentation of Alzheimer’s disease. Cortex. 2008;44(2):185–95.

    Article  PubMed  Google Scholar 

  99. Tractenberg RE, Pietrzak RH. Intra-individual variability in Alzheimer’s disease and cognitive aging: definitions, context, and effect sizes. PLoS One. 2011;6(4):e16973.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Tarnanas I, Tsolaki A, Wiederhold M, Wiederhold B, Tsolaki M. Five-year biomarker progression variability for Alzheimer’s disease dementia prediction: can a complex instrumental activities of daily living marker fill in the gaps? Alzheimers Dement Diagn Assessment Dis Monit. 2015;1(4):521–32.

    Article  Google Scholar 

  101. Zolochevska O, Bjorklund N, Woltjer R, Wiktorowicz J, Taglialatela G. Postsynaptic proteome of non-demented individuals with Alzheimer’s disease neuropathology. J Alzheimers Dis. 2018. https://doi.org/10.3233/JAD-180179.

  102. Sturmberg J, Topolski S. For every complex problem, there is an answer that is clear, simple and wrong. J Eval Clin Pract. 2014;20(5):1017–25.

    Article  PubMed  Google Scholar 

  103. Mittra I. The disconnection between tumor response and survival. Nat Clin Pract Oncol. 2007;4(4):203.

    Article  PubMed  Google Scholar 

  104. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G, On behalf of the Solid Tumors Working Party of the European Group for B and Marrow T. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst. 2008;100(8):533–41.

    Article  CAS  PubMed  Google Scholar 

  105. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

    Article  PubMed Central  Google Scholar 

  106. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. Br Med J. 2011;343:d6898.

    Article  Google Scholar 

  107. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012;380(9855):1741–8.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64(6):588–97.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Musini V, Gueyffier F, Puil L, Salzwedel D, Wright J. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev. 2017;8:CD008276.

    PubMed  Google Scholar 

  110. Gorricho J, Garjón J, Celaya M, Muruzába lL, Malón M, Montoya R, López A. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2017;10:CD010315.

    PubMed  Google Scholar 

  111. Ioannidis JA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018;319:115–116.

    Article  PubMed  Google Scholar 

  112. Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, on behalf of the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955–965.

    PubMed  Google Scholar 

  113. Garrison S, Kolber M, Korownyk C, McCracken R, Heran B, Allan G. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017;8:CD011575.

    PubMed  Google Scholar 

  114. Sturmberg J. Hype and tension in hypertension. Debating the latest hypertension guidelines. Eur J Pers Cent Healthc. 2018;6(1):128–37.

    Article  Google Scholar 

  115. Heath I. Combating disease mongering: daunting but nonetheless essential. PLoS Med. 2006;3(4):e146. Available at www.plosmedicine.org.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Black W. Advances in radiology and the real versus apparent effects of early diagnosis. Eur J Radiol. 1998;27(2):116.

    Article  CAS  PubMed  Google Scholar 

  117. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.

    Article  PubMed  Google Scholar 

  118. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. Br Med J. 2012;344:19–23.

    Article  Google Scholar 

  119. Yver M. Surgical pathology in cancer diagnosis: implications for quaternary prevention. Rev Bras Med Fam Comunidade. 2015;10(35):7.

    Article  Google Scholar 

  120. Moynihan R, Nickel B, Hersch J, Beller E, Doust J, Compton S, Barratt A, Bero L, McCaffery K. Public opinions about overdiagnosis: a national community survey. PLoS One. 2015;10(5):e0125165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Welch HG, Fisher ES. Income and cancer overdiagnosis - when too much care is harmful. N Engl J Med. 2017;376(23):2208–9.

    Article  PubMed  Google Scholar 

  122. Herndon MB, Schwartz LM, Woloshin S, Welch HG. Implications of expanding disease definitions: the case of osteoporosis. Health Aff (Millwood). 2007;26(6):1702–11.

    Article  Google Scholar 

  123. Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PLoS Med. 2008;5:e106.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Drugwatch. Disease mongering and drug marketing. 2018. https://www.drugwatch.com/news/2012/01/22/disease-mongering-and-drug-marketing/.

  125. Wolinsky H. Disease mongering and drug marketing. EMBO Rep. 2005;6(7):612–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Brezis M. Big pharma and health care: unsolvable conflict of interests between private enterprise and public health. Isr J Psychiatry Relat Sci. 2008;45(2):83–9.

    PubMed  Google Scholar 

  127. Prasad V, Cifu A, Ioannidis JPA. Reversals of established medical practices. evidence to abandon ship. JAMA. 2012;307(1):37–8.

    Article  CAS  PubMed  Google Scholar 

  128. Prasad V. Powering cancer screening for overall mortality. ecancermedicalscience. 2013;7:ed27. https://ecancer.org/journal/editorial/27-powering-cancer-screening-for-overall-mortality.php.

  129. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”—and what we can do about it. Br Med J. 2016;352:h6080.

    Article  CAS  Google Scholar 

  130. Jacklyn G, Bell K, Hayen A. Assessing the efficacy of cancer screening. Public Health Res Pract. 2017;27(3):e2731727.

    Article  Google Scholar 

  131. AIHW. Medical practitioners workforce 2015. 2016. https://www.aihw.gov.au/reports/workforce/medical-practitioners-workforce-2015/contents/how-many-medical-practitioners-are-there.

  132. Health Workforce Australia. Australia’s future health workforce - nurses detailed. Canberra: Department of Health; 2014.

    Google Scholar 

  133. Sturmberg JP, M O’Halloran D, McDonnell G, M Martin C. General practice work and workforce. Aust J Gen Pract. 2018;47:507–13.

    PubMed  Google Scholar 

  134. Sturmberg JP, O’Halloran DM, Martin CM. People at the centre of complex adaptive health systems reform. Med J Aust. 2010;193(8):474–8.

    PubMed  Google Scholar 

  135. Sturmberg JP, O’Halloran DM, Martin CM. Health care reform - the need for a complex adaptive systems approach. In: Sturmberg JP, Martin CM, editors. Handbook of systems and complexity in health. New York: Springer; 2013. p. 827–53.

    Chapter  Google Scholar 

  136. Adler KG. Does high patient satisfaction mean high quality of care? Fam Pract Manag. 2016;23(3):4.

    PubMed  Google Scholar 

  137. Kupfer JM, Bond EU. Patient satisfaction and patient-centered care: necessary but not equal. JAMA. 2012;308(2):139–40.

    Article  CAS  PubMed  Google Scholar 

  138. Enguidanos ER, Coletti CM, Honigman L, Mazzeo A, Pinson TB, Reed K, Wiler JL. Patient satisfaction surveys and quality of care: an information paper. Ann Emerg Med. 2014;64(4):351–7.

    Article  PubMed  Google Scholar 

  139. Dunsch F, Evans DK, Macis M, Wang Q. Bias in patient satisfaction surveys: a threat to measuring healthcare quality. BMJ Global Health. 2018;3(2):e000694.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Howie J, Heaney D, Maxwell M, Walker J. A comparison of a Patient Enablement Instrument (PEI) against two established satisfaction scales as an outcome measure of primary care. Fam Pract. 1998;15:165–71.

    Article  CAS  PubMed  Google Scholar 

  141. Porter ME, Larsson S, Lee TH. Standardizing patient outcomes measurement. N Engl J Med. 2016;374(6):504–6.

    Article  CAS  PubMed  Google Scholar 

  142. Sepucha KR, Levin CA, Uzogara EE, Barry MJ, O’Connor AM, Mulley AG. Developing instruments to measure the quality of decisions: early results for a set of symptom-driven decisions. Patient Educ Couns. 2008;73(3):504–10.

    Article  PubMed  Google Scholar 

  143. Lee CN, Dominik R, Levin CA, Barry MJ, Cosenza C, O’Connor AM, Mulley Jr AG, Sepucha KR. Development of instruments to measure the quality of breast cancer treatment decisions. Health Expect. 2010;13(3):258–72.

    PubMed  PubMed Central  Google Scholar 

  144. Annas GJ. Reframing the debate on health care reform by replacing our metaphors. N Engl J Med. 1995;332(11):745–8.

    Article  Google Scholar 

  145. Starfield B. Is US health really the best in the world? JAMA. 2000;284(4):483–5.

    Article  CAS  PubMed  Google Scholar 

  146. Macinko J, Starfield B, Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970–1998. Health Serv Res. 2003;38(3):831–65.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Macinko J, Starfield B, Shi L. Quantifying the health benefits of primary care physician supply in the United States. Int J Health Serv. 2007;37(1):111–26.

    Article  PubMed  Google Scholar 

  148. Hart J. The inverse care law. Lancet. 1971;I:405–12.

    Google Scholar 

  149. Katerndahl DA, Wood R, Jaen CR. A method for estimating relative complexity of ambulatory care. Ann Fam Med. 2010;8(4):341–7.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4(2):104–8.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Greenfield S, Kaplan S, Kahn R, Ninomiya J, Griffith J. Profiling care provided by different groups of physicians: effects of patient case-mix (Bias) and physician-level clustering on quality assessment results. Ann Intern Med. 2002;136:111–21.

    Article  PubMed  Google Scholar 

  152. Greenfield S, Rogers W, Mangotich M, Carney M, Tarlov A. Outcomes of patients with hypertension and non-insulin-dependent diabetes mellitus treated by different systems and specialties. JAMA. 1995;274(18):1436–44.

    Article  CAS  PubMed  Google Scholar 

  153. Scott JG. Complexities of the consultation. In: Sturmberg JP, Martin CM, editors. Handbook of systems and complexity in health. New York: Springer; 2013. p. 257–77.

    Chapter  Google Scholar 

  154. Hjortdahl P. Continuity of care: general practitioners’ knowledge about, and sense of responsibility toward their patients. Fam Pract. 1992;9(1):3–8.

    Article  CAS  PubMed  Google Scholar 

  155. Fugelli P. Trust - in general practice. Br J Gen Pract. 2001;51(468):575–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  156. Freeman G, Olesen F, Hjortdahl P. Continuity of care: an essential element of modern general practice? Fam Pract. 2003;20(6):623–7.

    Article  PubMed  Google Scholar 

  157. Hjortdahl P. The influence of general practitioners’ knowledge about their patients on the clinical decision-making process. Scand J Prim Health Care. 1992;10:290–4.

    Article  CAS  PubMed  Google Scholar 

  158. Sturmberg JP, Schattner P. Personal doctoring. Its impact on continuity of care as measured by the comprehensiveness of care score. Aust Fam Physician. 2001;30(5):513–8.

    CAS  PubMed  Google Scholar 

  159. Saultz JW, Lochner J. Interpersonal continuity of care and care outcomes: a critical review. Ann Fam Med. 2005;3(2):159–66.

    Article  PubMed  PubMed Central  Google Scholar 

  160. Guthrie B, Saultz JW, Freeman GK, Haggerty JL. Continuity of care matters. Br Med J. 2008;337(aug07_1):a867.

    Google Scholar 

  161. Sweeney K, Gray D. Patients who do not receive continuity of care from their general practitioner - are they a vulnerable group? Br J Gen Pract. 1995;45:133–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  162. Sturmberg JP. Health system redesign. How to make health care person-centered, equitable, and sustainable. Cham: Springer; 2017.

    Google Scholar 

  163. Sturmberg JP, Martin CM. The dynamics of health care reform - learning from a complex adaptive systems theoretical perspective. Nonlinear Dynam Psych Life Sci. 2010;14(4): 525–40.

    Google Scholar 

  164. Ellis GFR. Top-down causation and emergence: some comments on mechanisms. Interface Focus. 2012;2(1):126–40.

    Article  PubMed  Google Scholar 

  165. Rothman KJ. Causes. Am J Epidemiol. 1976;104(6):587–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Appendices

Appendix 1: Disease Definitions and Re-definitions

Hypertension

1948

The blood pressure is [considered to be] raised when the systolic pressure is 180 or over, and/or the diastolic pressure is 110 or over, on three consecutive examinations, and in the presence of clinical, radiological and cardiographic evidence of cardiovascular hypertrophy.— Evans W. Hypertension. In: Cardiology. London, England: Paul B. Hoeber, Inc; 1948:204

1949

In a patient with mild benign hypertension—[defined as a] blood pressure ¡200/¡100mmHg, there is no indication for use of hypotensive drugs. Continued observation is desirable and conservative treatment consisting of reassurance, mild sedatives, and weight reduction is indicated.— Friedberg CK. Diseases of the Heart. Philadelphia, PA: WB Saunders Co; 1949

1960s

Hypertension = BP > 100+age

1977

JNC 1— Moser M. From JNC I to JNC 7-what have we learned? Prog Cardiovasc Dis. 2006;48:303–315

• Diastolic BP >105 mm Hg requires treatment

2003

JNC 7— Moser M. From JNC I to JNC 7-what have we learned? Prog Cardiovasc Dis. 2006;48:303–315

• Normal BP 120–129/80–89

2017

American College of Cardiology/American Heart Association (ACC/AHA) guidelines—Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD and Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71(6):1269–324

• Hypertension >130/80 mm Hg

Diabetes mellitus—definition is based on occurrence of diabetic retinopathy

1979

National Diabetes Data Group—Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979 Dec;28(12):1039–57

 

Based on 77 out of 1213 people developing retinopathy

• Fasting plasma glucose (FPG) concentration of ≥ 7.8 mmol/L (140 mg/dL), or

• 2-h value after 75 g oral glucose of ≥ 11.1 mmol/L (200 mg/dL)

1997

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus—Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183–97

 

Diagnosis of diabetes by linking levels of glycaemia with diabetic retinopathy in populations of Pima Indians (n = 960), Egyptians (n = 1081), and a randomly selected cohort in the Third National Health and Nutrition Examination Survey (NHANES III) (n = 2821)

• Fasting plasma glucose (FPG) criterion of ≥ 7.0 mmol/L (126 mg/dL)

Diabetes mellitus—definition is based on occurrence of diabetic retinopathy

2010

American Diabetes Association— Diagnosis and classification of diabetes mellitus. American Diabetes Association. Diabetes Care. 2010;33(Suppl 1):S62–9

• HbA1c levels ≥ 6.5%

Depression—disease or syndrome

1920s–1970s

Textbook definitions of endogenous and reactive depression:

• Endogenous depression (severe disorder with delusions and hallucinations)

• Reactive depression (milder disorder without delusions and hallucinations; often with the connotation of a vulnerable personality, in the context of life stresses, features of diurnal variation with morning worsening, delayed insomnia with early morning wakening and greater somatic disturbances, such as loss of appetite and weight, and psychomotor retardation or agitation

2013

DSM-V major depression

 

(A) Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure

 

Note: Do not include symptoms that are clearly attributable to another medical condition

1. Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad, empty and hopeless) or observation made by others (e.g. appears tearful). (Note: In children and adolescents, can be irritable mood)

Depression—disease or syndrome

 

2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation)

3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (Note: In children, consider failure to make expected weight gain)

4. Insomnia or hypersomnia nearly every day

5. Psychomotor agitation or retardation nearly every day observable by others, not merely subjective feelings of restlessness or being slowed down)

6. Fatigue or loss of energy nearly every day

7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)

8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)

9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide

 

(B) The symptoms cause clinically significant distress or impairment in social, occupational or other important areas of functioning

 

(C) The episode is not attributable to the physiological effects of a substance or to another medical condition

 

Note: Criteria A–C represent a major depressive episode

 

Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a natural disaster, a serious medical illness or disability) may include the feelings of intense sadness, rumination about the loss, insomnia, poor appetite and weight loss noted in Criterion A, which may resemble a depressive episode

 

Although such symptoms may be understandable or considered appropriate to the loss, the presence of a major depressive episode in addition to the normal response to a significant loss should also be carefully considered. This decision inevitably requires the exercise of clinical judgment based on the individual’s history and the cultural norms for the expression of distress in the contest of loss

 

(D) The occurrence of the major depressive episode is not better explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder or other specified and unspecified schizophrenia spectrum and other psychotic disorders

 

(E) There has never been a manic episode or a hypomanic episode. Note: This exclusion does not apply if all of the manic-like or hypomanic like episodes are substance-induced or are attributable to the physiological effects of another medical condition

DSM-V adjustment disorder

 

• Emotional or behavioural symptoms develop in response to an identifiable stressor or stressors within 3 months of the onset of the stressor(s) plus either or both of (1) marked distress that is out of proportion to the severity or intensity of the stressor, even when external context and cultural factors that might influence symptom severity and presentation are taken into account and/or (2) significant impairment in social, occupational or other areas of functioning

• The stress-related disturbance does not meet criteria for another mental disorder and is not merely an exacerbation of a pre-existing mental disorder

• The symptoms do not represent normal bereavement

• After the termination of the stressor (or its consequences), the symptoms persist for no longer than an additional 6 months

Appendix 2: Prevalence of Long-Term Conditions in the Australian National Health Survey

 

2001a

2014b

Arthritis

 

15.3% (3.5 million people)

Asthma

12% (2.2 million people)

10.8% (2.5 million people)

Cancer

1.6% (311,300 people)

1.6% (370,100 people)

High cholesterol

6.0% (1.1 million people)

7.1% (1.6 million people)

Diabetes

2.9% (554,200 people)

5.1% (1.2 million people)

Heart disease

 

5.2% (1.2 million people)

Hypertension

10% (1.8 million people)

11.3% (2.6 million people)

Kidney disease

 

0.9% (203,400 people)

Mental and behavioural conditions

18% (3.3 million people)

17.5% (4.0 million people)

Osteoporosis

 

3.5% (801,800 people)

  1. aAustralian Bureau of Statistics. National Health Survey. Australia 2001. http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/90A3222FAD5E3563CA256C5
  2. D0001FD9D/\protect\T1\textdollarFile/43640_2001.pdf
  3. bAustralian Bureau of Statistics. National Health Survey. First Results Australia 2014–15. http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/CDA852A349B
  4. 4CEE6CA257F150009FC53/\protect\T1\textdollarFile/national%20health%20sur
  5. vey%20first%20results,%202014-15.pdf

Appendix 3: Annas’ Analysis of the Consequences of the Military and Market Metaphors on Health Care [144]

Military metaphor

Consequences

• Medicine is a battle against death

• We are almost constantly engaged in wars on various diseases, such as cancer and AIDS

• Diseases attack the body, patients fight the disease and doctors intervene or counterattack

• Doctors are mostly specialists and backed by allied health professionals all of whom are trained to be aggressive, fight these invading diseases with weapons designed to knock them out

• Doctors give orders in the trenches and on the front lines, using their armamentaria in search of breakthroughs

• Treatments are conventional or heroic, and the brave patients soldier on

• We engage in triage in the emergency department, invasive procedures in the operating theatre, and even defensive medicine when a legal enemy is suspected

• Health plans and hospitals market products to consumers, who purchase them on the basis of price

• Medical care is a business that necessarily involves marketing through advertising and competition amongst suppliers who are primarily motivated by profit

• Health care becomes managed care

Mergers and acquisitions become core activities

• Ignore costs

• Strengthens the belief that all problems can be solved with more sophisticated technology and scientific advances, prompting hospitals and doctors to engage in medical arms races

• War analogies lead to acceptance as inevitable that organisations are hierarchical and largely dominated by men

• The patient’s body becomes a battlefield, thus appropriate to have short-term, single-minded tactical goals

• Concentrates on the physical, sees control as central and encourages the expenditure of massive resources to achieve dominance

• We failed to assert that medicine, like war, should be financed and controlled only by the government

• The metaphor has also become mythic. As a historian of war, John Keegan, correctly argues, modern warfare has become so horrible that ‘it is scarcely possible anywhere in the world today to raise a body of reasoned support for the opinion that war is a justifiable activity’

• Emphasis is placed on:

Efficiency

Profit maximisation

Customer satisfaction

The ability to pay

Planning

Entrepreneurship

Competitive models

• The ideology of medicine is displaced by the ideology of the marketplace

• Trust is replaced by caveat emptor

Chains are developed, vertical integration is pursued and antitrust worries proliferate

Consumer choice becomes the central theme of the market metaphor

• In the language of insurance, consumers become ‘covered lives’ or even ‘money-generating biological structures’

• Economists become health-financing gurus

• The role of doctors is radically altered as they are instructed by managers that they can no longer be patient advocates (but instead must advocate for the entire group of covered lives in the health plan)

• The goal of medicine becomes a healthy bottom line instead of a healthy population

• There is no place for the poor and uninsured in the market metaphor

Business ethics supplant medical ethics as the practice of medicine becomes corporate

Non-profit medical organisations may tend to be corrupted by adopting the values of their for-profit competitors

• A management degree becomes at least as important as a medical degree

Public institutions, which by definition cannot compete in the for-profit arena, risk demise, second-class status or simply privatisation

Patients, as consumers, are to make decisions that are governed by corporate entities

• The market metaphor conceals the inherent imperfections of the market and ignores the public nature of many aspects of medicine

It ignores the inability of the market to distribute goods and services whose supply and demand are unrelated to price

• The metaphor pretends that there is such a thing as a free market in health insurance plans and that purchasers can and should be content with their choices when unexpected injuries or illnesses strike them or their family members

• The reality is that American markets are:

– Highly regulated,

– Major industries enjoy large public subsidies,

– Industrial organisations tend towards oligopoly and

– Require strong laws that protect consumers and offer them recourse through product-liability suits to prevent profits from being too ruthlessly pursued

  1. Compiled from Annas: reframing the debate on healthcare reform by replacing our metaphors; italics emphasise pertinent concepts from the paper. Taken from: Sturmberg et al. [135]

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sturmberg, J.P. (2019). If You Change the Way You Look at Things, Things You Look at Change. Max Planck’s Challenge for Health, Health Care, and the Healthcare System. In: Sturmberg, J. (eds) Embracing Complexity in Health. Springer, Cham. https://doi.org/10.1007/978-3-030-10940-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-10940-0_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-10939-4

  • Online ISBN: 978-3-030-10940-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics